Novartis ESMO Event Presentation

Ambition to transform advanced prostate cancer across four main segments with Pluvicto studies 4 PSMA-DC 3 PSMAddition 2 PSMAfore 1 VISION Local PC US: 283k BCR US: 41k Localized Locoregional nmCRPC US: 33k Locoregional m HSPC US: 39k mCRPC 1L US: 42k 2L+ US: 27k Metastatic Source: Cerner Enviza 2023 US Prostate Cancer Incidence PC = prostate cancer BCR biochemical recurrence nmCRPC = non-metastatic castration-resistant prostate cancer mCRPC metastatic castration-resistant prostate cancer 8 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION mHSPC metastatic hormone-sensitive prostate cancer NOVARTIS | Reimagining Medicine

View entire presentation